News · 26 weeks70+17%
2026-03-012026-08-23
Mix2990d
- SEC Filings9(31%)
- Insider9(31%)
- Other8(28%)
- Leadership2(7%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Financial Officer Levy Raphi exercised 2,871 units of Ordinary Shares at a strike of $2.98 and sold $43,073 worth of Ordinary Shares (2,871 units at $15.00) (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- PRNano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation CommitteeWALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano," or the "Company") today announced the appointment of Nadav Kidron to its Board of Directors (the "Board"). As part of the Board’s ongoing strategic review, led by Chairman Phillip Borenstein, the Board intends to establish a Strategy and Capital Allocation Committee to support the Board’s evaluation of capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets, strategic opportunities and other initiatives intended to maximize long-term shareholder value. Mr. Kidron will chair this committee and work with the Chairman, hi
- INSIDERChief Financial Officer Levy Raphi exercised 17,730 units of Ordinary Shares at a strike of $2.98 and sold $248,277 worth of Ordinary Shares (17,730 units at $14.00) (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites - - Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing Alpha DaRT supply agreement at 60% of net sales, subje
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets. "After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home," commented Uzi Sofer, CEO of Alpha Tau. "The Israeli investor market has been expressing ever-growing interest of late in our progress and in the potential of our technology, and we have received many r
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting - - Median overall survival of 18.2 months and median progression-free survival of 5.4 months compare favorab
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson team, led by Dr. Samuels, has also treated multiple patients - - Immunocompromised patients face dramatically higher rates of cSCC, the second most common type of skin cancer in the U.S., than the general population - as much as 65- to 100-fold among organ transplant recipients specifically - - For many patients in this population, the general treatment options for recurrent cSCC can actually cause real harm: checkpoint inhibitor immunotherapy, the standard option for the g
- INSIDERChief Financial Officer Levy Raphi sold $31,782 worth of Ordinary Shares (2,270 units at $14.00) and exercised 2,270 units of Ordinary Shares at a strike of $2.98 (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi exercised 17,873 units of Ordinary Shares at a strike of $2.98 and sold $232,397 worth of Ordinary Shares (17,873 units at $13.00) (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi exercised 2,127 units of Ordinary Shares at a strike of $2.98 and sold $27,691 worth of Ordinary Shares (2,127 units at $13.02) (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi sold $240,044 worth of Ordinary Shares (20,000 units at $12.00), decreasing direct ownership by 18% to 90,180 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi sold $220,004 worth of Ordinary Shares (20,000 units at $11.00), decreasing direct ownership by 15% to 110,180 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PROramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetSignificant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
- INSIDERChief Financial Officer Levy Raphi sold $167,051 worth of Ordinary Shares (17,500 units at $9.55), decreasing direct ownership by 12% to 130,180 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s premier academic neurosurgical institutions - - The procedure marks the first international clinical application of Alpha DaRT’s brain-specific proprietary delivery system - - Glioblastoma is the most common and aggressive primary brain cancer, with approximately 160,000 new cases diagnosed globally each year; with recurrence occurring in virtually all patients, typically within 6-9 months, for which there is no established standard of care - - The patient was treated under the ALL clinical proto
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven patients in the trial - - Marks the latest in a series of regulatory successes in this indication, following FDA's recognition of Alpha DaRT's potential through its Breakthrough Device Designation for recurrent glioblastoma (GBM) and Alpha Tau's selection for the FDA's prestigious Total Product Life Cycle (TPLC) Advisory Program (TAP) - - With approximately 14,000 Americans newly diagnosed with glioblastoma each year and median survival after recurrence typically measured in months, Alpha D
- INSIDERChief Financial Officer Levy Raphi sold $352,115 worth of Ordinary Shares (32,500 units at $10.83), decreasing direct ownership by 18% to 147,680 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
DRTS FAQ
6 questionsWhat does Alpha Tau Medical Ltd. do?
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Where does DRTS stock trade?
Alpha Tau Medical Ltd. (DRTS) is listed on NASDAQ.What sector and industry is DRTS in?
Alpha Tau Medical Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about DRTS?
Alpha Tau Medical Ltd. has had 7 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $1500.00 price target on 2026-05-28. Recent price targets range from $500.00 to $2100.00.What companies are similar to DRTS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare DRTS side-by-side with any of them on Quantisnow.How can I track DRTS on Quantisnow?
Quantisnow aggregates Alpha Tau Medical Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRTS to receive live email and push alerts on every new disclosure.